Plain-English translation of NCT07262983 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a medication called to see if it is safe and tolerable for people with Job syndrome—a rare genetic immune disorder—who also have lupus-like symptoms and/or severe eczema. works by affecting how the immune system functions. The researchers want to learn whether this treatment helps improve symptoms while being safe for patients with this complex condition.
Job syndrome is a rare genetic condition that affects the immune system, making people more prone to infections and skin problems like severe eczema. Some patients also develop lupus-like symptoms. Currently, there are limited treatment options for these patients, so researchers are testing this medication to see if it could help control symptoms safely.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first have a 3-month screening period where you track your infections and skin symptoms to make sure your disease is stable. Then, if you qualify, you will take by mouth for 6 months while researchers monitor you for safety and track any changes in your infections, lupus-like symptoms, and eczema. You will have regular visits to report how you're doing and complete assessments of your symptoms and quality of life.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
United States